Targeted therapies that rely on the expression of the estrogen receptor (ER), progesterone receptor (PgR) and epidermal growth factor receptor 2 (HER2) are effective treatments for luminal and HER2+ breast cancers [3]. This evidence concerns the gene ERBB2 and breast carcinoma.